International Journal of Clinical Biochemistry and Research

Print ISSN: 2394-6369

Online ISSN: 2394-6377

CODEN : IJCBK6

International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 491

PDF Downloaded: 1741


Get Permission Thomas and Mithrason: A review on biomarkers of hypertension


Introduction

Hypertension (HTN) is a major global health burden. It is the most prevalent chronic medical condition seen in primary care.1 It is responsible for 10.8% of all deaths in India.2 It effects various organ like heart, kidney, brain, eyes, etc. HTN is directly responsible for 57% of all stroke deaths and 24% of all coronary heart disease deaths in India. It is a controllable disease. A 2mmHg population-wide decrease in BP can prevent 151,000 stroke and 153,000 coronary heart disease deaths in India.3

HTN is divided into 2 groups: primary (or essential) and secondary hypertension. Essential hypertension has no clear etiology and accounts for 95% of cases. Secondary hypertension accounts for the remaining 5% of cases.4 It has many clinical patterns and/or etiopathological forms which includes: essential HTN, secondary HTN, white-coat HTN, isolated systolic HTN, masked HTN, pulmonary HTN, pregnancy related HTN.1 Clinical or office measurement of blood pressure (BP) is the classical diagnosis of HTN. It is defined as persistent elevation in office systolic BP ≥ 140 mmHg and or diastolic BP ≥ 90 mmHg. This is equivalent to a 24 hr ambulatory BP monitoring average of ≥ 130/80 mmHg or a home BP monitoring average ≥ 135/85 mmHg.5

Regardless of the device used to assess BP, the conventional practice only provides us with values and patterns. A significant proportion of hypertensive patients are diagnosed at an advanced stage of the disease, because of the “silent” nature of the disease in most cases.6 According to the latest European guidelines hypertension is diagnosed when BP is >140/90 mm Hg, whereas according to the American guidelines hypertension is diagnosed when BP >130/80 mm Hg. It is proven that in Indian population BP levels between 130 to 139/80 to 89 mm Hg can lead to higher risk of CVD, stroke, and premature mortality.7 Thus the newer (lower) thresholds for goal BP according to American guidelines might seem unattainable but if the country adopts it can be protective to Indian population.

Gold standard for blood pressure measurement is using mercury sphygmomanometer.8 But poor standardized techniques of BP measurement, poor calibration of device and diagnosis based on single measurement are few challenges in India. Therefore, laboratory tests could predict not only the risk of development of HTN, but also in treatment of individual patients by helping to choose the right drug for the right patient, and also can help in monitoring the control of HTN throughout the treatment period, help in risk stratification of the patients by prognosis, and predict and prevent hypertensive end organ damage.9

Multiple biomarkers for HTN have been identified over the years and may shed light on the underlying processes involved in the development and progression of HTN. Here, we discuss the important biomarkers of HTN to help better evaluate their utility and to better understand the pathophysiology, diagnosis, progression, and therapeutic efficacy of EH.

Materials and Methods

A Pubmed and google scholar search was performed, using “hypertension”, “biomarkers” and “markers” as search parameters, and also their relevant references were reviewed. No limitation was placed on years included in the study. A total of 150 articles were read and analysed with particular focus on usefulness of the biomarker. Studies were excluded if they were not relevant and practically feasible. 64 remaining articles were found relevant and reviewed further. The included studies described number of biomarkers of which five biomarkers i.e., C-reactive protein, cytokines, uric acid, urine albumin excretion and nitric oxide were considered for this study because of its feasibility.

Discussion

Genetic and environmental factors contribute to development of HTN. Also, a complex interactions of various hormones, local vascular factors, and neural mechanisms have a role to play.10 The cause of secondary HTN includes primary hyperaldosteronism, Cushing's syndrome, etc. They have specific markers for diagnosis such as plasma metanephrine measurements, plasma aldosterone level, etc.1 On the other hand, though essential hypertension accounts for 95% of all cases of HTN, its etiology is not clear. Different patients have different etiology for high blood pressure.11 Endothelial dysfunctions, oxidative stress, and inflammation play a major role in its development Figure 1.12, 13, 14, 15, 16

Figure 1

Schematic diagram showing relationship between inflammation & HTN

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/2e73be63-7e49-4f84-bb5c-8f5118eab4e2/image/3aaefca1-3f3f-4740-af07-fc76f78cbfa5-uimage.png

In this section we discuss various biomarkers of hypertension. Of the many available markers C-reactive protein, cytokines, uric acid, urine albumin excretion and nitric oxide gives us better understanding of the progression of HTN.

C-reactive protein (CRP)

CRP is an inflammatory marker and is increased in several conditions like diabetes.17 Normally minimal amounts of CRP is present in plasma and the level increases to 100 fold when there is any injury, infection, or inflammation. CRP is the first acute phase protein to be described.18, 19 It is mainly synthesized by liver in response to interleukin-6 and interleukin-1ß. Its relation to essential HTN is extensively studied.20, 21, 22 Sesso et al. in their study demonstrated that with increased levels of CRP, risk of developing HTN increases.15 Similar findings were shown in another study by Wang et al.23

CRP increases the blood pressure by various mechanisms:

  1. It decreases the production of nitric oxide by endothelial cells,24, 25 and thus indirectly inhibits vasodilatation.

  2. It increases leukocyte adhesion, platelet activation, oxidation, and thrombosis.24, 25

  3. It also up regulates the angiotensin type-1 receptor, thus mediating the angiotensin-II mediated increase in blood pressure.11

CRP is very stable and have half-life of 19 hours with very little variation in values between fresh and frozen forms.26 Also it has a longer plasma half-life making it more reliable indicator of chronic inflammation.27 The only drawback is that it is not detectable at a very low level (i.e., <3 mg/l). Instead hsCRP (detectable at lower than 3 mg/l) can be used to detect pro-inflammatory state at the earliest. Sinha et al. in their study found increased hsCRP level positively related with increase in diastolic blood pressure in prehypertensives.28 Ki Chul Sung et al. in another study found hsCRP to be an independent risk factor for development of hypertension in Korean population.29

Cytokines

Cytokines are signalling proteins, which regulate a wide range of biological functions including innate and acquired immunity, haematopoiesis, inflammation and repair, and proliferation through mostly extracellular signalling. Pro-inflammatory cytokines include IL-1β, IL-6, and TNFα.30 IL-6 is a central mediator of the acute-phase response and a primary determinant of hepatic production of CRP, plus, IL-6 modulates the production of tumour necrosis factor and regulates the immune response.31 Circulating IL-6 also stimulates the hypothalamic– pituitary–adrenal axis, which, when activated, is also associated with hypertension.32

There are studies that have demonstrated increased cytokine (IL-1β, IL-6, TNF-α) levels in hypertensive patients compared to normotensive patients.30, 31, 32, 33 The link between cytokines and hypertension maybe:

  1. Various hemodynamic changes due to hypertension leads to endothelial dysfunction, and increase in levels of inflammatory markers such as interleukin-6 (IL-6), intracellular adhesion molecule 1 (ICAM1), P-selectin, and tumor necrosis factor-α (TNF-α).12, 13

  2. The renin-angiotensin system and sympathetic nervous system, play an important role in regulating blood pressure. They stimulate the release of proinflammatory cytokines (IL-6, TNF- α) and serve its source.34, 35 These cytokines in turn induce structural as well as functional alterations in endothelial cells.36, 37

  3. CRP by stimulating monocytes also release pro-inflammatory cytokines such as IL-6, IL-1ß and TNF-α which further promotes inflammation and effects endothelial function.37

  4. There is increasing evidence that excess adiposity, which is a major risk factor for hypertension, is characterized by broad inflammatory response.1, 38 This induces adipose tissue to release various cytokines and adipokines proteins39 and to create a chronic state of inflammation that may lead to hypertension.

Uric acid (UA)

UA is an end product of purine metabolism.40 It is 5% plasma protein bound, is freely filtered at the glomerulus, is 99% reabsorbed in the proximal tubule, secreted by the distal tubule, and subjected to considerable post secretory reabsorption. Fractional secretion of uric acid is about 7% to 10%.41 Serum UA serves as a useful marker of inflammation and oxidative stress in HTN.42 An elevated UA level is observed in nearly 90% of adolescents with essential hypertension of recent onset.43

A lot of studies have shown a significant association between uric acid levels, HTN and its cardiovascular complications in their study.44, 45 A study by Feig et al. found that by administering drugs such as allopurinol (used for treatment of hyperuricemia) in obese adolescents with pre-hypertension, resulted in marked BP control and reduction in systemic vascular resistance.43 Scheepers et al. in their study have also focussed on importance of uric acid and purine catabolism, and their potential association with essential hypertension.46 Association between hypertension and increased UA was first seen in 1957.47

UA is thought to play a role in HTN via mechanisms like inflammation, vascular smooth muscle cell proliferation in renal microcirculation, endothelial dysfunction, down regulation of nitric oxide (NO) production and activation of the rennin – angiotensin – aldosterone system.48, 49 This hypertension type is salt‑resistant in that it occurs even in the presence of a low‑salt diet, and it responds to lowering of UA.49 The role played by UA in pathogenesis of early onset HTN decreases with increase in age. With increase in age, stiffening of the aorta, activation of RA- system and renal vasoconstriction have a role to play.50 Various studies have found a higher mean UA concentration in pre-hypertensives who were averagely younger.45, 49, 51

Urine albumin excretion (UAE)

The detection and quantification of albumin in urine is commonly used for screening of diabetic and hypertensive nephropathy, as well as preeclampsia. It’s an early marker of renal damage.52 UAE predicts the development of hypertension, independent of BP and other widely known risk factors for development of hypertension.53 There are studies which found risk of developing HTN was highest with increase in UAE.54 This can be explained by following mechanisms:

  1. UAE reflects damage to the renal microvasculature which causes generalized endothelial dysfunction, thus causing hypertension.55, 56

  2. Reduction in number of nephrons also provides a link between higher albumin excretion and the development of hypertension.57

  3. GFR is mildly reduced when there is reduction in glomerular filtration surface area thereby limiting excretion of sodium and causing hypertension.58

Nitric oxide

Nitric oxide(NO) is generated from its precursor L-arginine by nitric oxide synthase (NOS). Inflammation has been shown to downregulate NOS activity.59 Research data suggests impaired NO activity is associated with HTN. Increased ROS and an altered balance between NO and ROS lead to impaired bioavailability of NO, resulting in decreased endothelium-dependent vasodilation, which, in turn, causes or exacerbates hypertension.60, 61 Impaired NO dependent vasodilation due to an imbalance between vasoconstrictors and vasodilators precedes hypertension.62

Conclusion

HTN is a chronic disease which causes severe complications like CAD, heart failure, stroke, etc. Inflammation can lead to the development of hypertension and oxidative stress and endothelial dysfunction which is associated with inflammation contributes to hypertension, by exacerbating the inflammatory response. Thus, biomarkers like C-reactive protein, cytokines, uric acid, urine albumin excretion and nitric oxide gives us better understanding of the progression of HTN.

Source of Funding

None.

Conflict of Interest

None.

References

1 

A Kossaify M Karam Markers in Hypertension: Insights for an Enhanced Blood Pressure ManagementJ Hypertens2014316510.4172/2167-1095.1000165

3 

A Rodgers C Lawes S Macmahon Reducing the global burden of blood pressure-related cardiovascular diseaseJ Hypertens Suppl200018136

4 

DJ Benos Biochemistry in Medicine: Hypertension Minireview SeriesJ Biol Chem2010285128507

5 

B Williams G Mancia Ten Commandments of the 2018 ESC/ESH HTN Guidelines on Hypertension in AdultsEur Heart J2018393330078

6 

G Mancia R Fagard K Narkiewicz J Redon A Zanchetti M Böhm 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens2013317128157

7 

HK Chopra CV Ram Recent guidelines for hypertension: a clarion call for blood pressure control in IndiaCirc Res201912479846

8 

H Tolonen P Koponen A Naska S Männistö G Broda T Palosaari Challenges in standardization of blood pressure measurement at the population levelBMC Med Res Methodol20151533

9 

S Pattanaik Biomarkers in essential hypertensionKidney BiomarkersAcademic Press202024788

10 

D Tsounis G Bouras G Giannopoulos C Papadimitriou D Alexopoulos S Deftereos Inflammation markers in essential hypertensionMed Chem201410767281

11 

B Rodríguez-Iturbe H Pons Y Quiroz RJ Johnson The immunological basis of hypertensionAm J Hypertens20142711132737

12 

C Savoia EL Schiffrin Inflammation in hypertensionCurr Opin Nephrol Hypertens20061521528

13 

Z Huang C Chen S Li F Kong P Shan W Huang Serum markers of endothelial dysfunction and inflammation increase in hypertension with prediabetes mellitusGenet Test Mol Biomarkers20162063227

14 

PM Ridker JE Buring NR Cook N Rifai C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American womenCirculation200310733917

15 

GM Hirschfield MB Pepys C-reactive protein and cardiovascular disease: new insights from an old moleculeQJM20039611793807

16 

M Di Napoli M Schwaninger R Cappelli E Ceccarelli G Di Gianfilippo C Donati Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project membersStroke2005366131629

17 

HD Sesso MC Jiménez L Wang PM Ridker JE Buring JM Gaziano Plasma inflammatory markers and the risk of developing hypertension in menJ Am Heart Assoc201549e001802

18 

HD Sesso L Wang JE Buring PM Ridker JM Gaziano Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in womenHypertension200749230410

19 

CH Wang SH Li RD Weisel PW Fedak AS Dumont P Szmitko C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscleCirculation2003813178390

20 

TJ Wang P Gona MG Larson D Levy EJ Benjamin GH Tofler Multiple biomarkers and the risk of incident hypertensionHypertension20074934328

21 

S Sinha K Kar M Soren A Dasgupta hsCRP in pre-hypertension and hypertension: a prospective study in Southern Asian regionInt J Res Med Sci20172414027

22 

HD Sesso JE Buring N Rifai GJ Blake JM Gaziano PM Ridker C-reactive protein and the risk of developing hypertensionJAMA200329022294551

23 

S Black I Kushner D Samols C-reactive proteinJ Biol Chem2004279474848790

24 

CJ Boos GYH Lip Elevated high-sensitivity Creactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension?J Hum Hypertens20051975113

25 

DC Wirtz KD Heller O Miltner KW Zilkens JM Wolff Interleukin-6: a potential inflammatory marker after total joint replacementInt Orthop20002441946

26 

KC Sung JY Suh BS Kim JH Kang H Kim MH Lee High sensitivity C-reactive protein as an independent risk factor for essential hypertensionAm J Hyperten200316642933

27 

J M Zhang J An Cytokines, inflammation, and painInt Anesthesiol Clin20074522737

28 

AP Wheeler GR Bernard Treating patients with severe sepsisN Engl J Med1999340320714

29 

JS Yudkin M Kumari SE Humphries V Mohamed-Ali Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?Atherosclerosis2000148220914

30 

A Pandey Y Saxena S Manna A Kotwal Study of Inflammatory Marker IL-6 and Sympathetic Activity Among WHR Matched Prehypertensive & Normotensive MalesIndian J Physiol Pharmacol201862330613

31 

V Bhaskar P Rao B Mahendran Correlative association of Interleukin-6 with malondialdehyde in prehypertensive and hypertensive subjectsJ Dent Med Sci2015147537

32 

S Zhao Q Li L Liu Z Xu J Xiao Simvastatin reduces interleukin-1β secretion by peripheral blood mononuclear cells in patients with essential hypertensionClin Chim Acta20043441-2195200

33 

R Thiyagarajana P Pala GK Pala SK Subramanianb M Trakrooc Z Bobbyd Markers of inflammation and insulin resistance in age and body mass index matched subjects with prehypertension and normotensionInt J Sci Res Pub20144616

34 

ZH Zhang SG Wei J Francis RB Felder Cardiovascular and renal sympathetic activation by blood-borne TNF-α in rat: the role of central prostaglandinsAm J Physiol Regul Integr Comp Physiol2003284491627

35 

D Sanz-Rosa MP Oubina E Cediel N De Las Heras O Vegazo J Jiménez Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-κB/IκB systemAm J Physiol Heart Circ Physiol200528811115

36 

M Ruiz-Ortega M Ruperez O Lorenzo V Esteban J Blanco S Mezzano Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidneyKidney Int Suppl2002821222

37 

SP Ballou G Lozanski Induction of inflammatory cytokine release from cultured human monocytes by C-reactive proteinCytokine1992453618

38 

JS Yudkin C Stehouwer J Emeis S Coppack C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arteriosclerosis, thrombosis, and vascular biologyArterioscler Thromb Vasc Biol19991949728

39 

RS Ahima JS Flier Adipose tissue as an endocrine organTrend Endocrinol Metab200011832732

40 

JC Nguedia Assob MN Ngowe DS Nsagha AL Njunda Y Waidim DN Lemuh The relationship between uric acid and hypertension in adults in Fako Division, SW region CameroonJ Nutr Food Sci201442572

41 

RJ Johnson DH Kang D Feig S Kivlighn J Kanellis S Watanabe Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal diseaseHypertension2003416118390

42 

A Shere O Eletta H Goyal Circulating blood biomarkers in essential hypertension: a literature reviewJ Lab Precis Med201721299

43 

DI Feig B Soletsky RJ Johnson Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trialJAMA2008300892432

44 

M Mazzali M Kanbay MS Segal M Shafiu D Jalal DI Feig Uric acid and hypertension: cause or effectCurr Rheumatol Rep201012210817

45 

J Sundstrom L Sullivan RB D'Agostino D Levy W B Kannel RS Vasan Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidenceHypertension20054512833

46 

LE Scheepers FF Wei K Stolarz-Skrzypek S Malyutina V Tikhonoff L Thijs Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population studyJ Hypertens20163411214754

47 

A Breckenridge Hypertension and HyperuricemiaLancet1966287158

48 

W Zhang K Sun Y Yang H Zhang FB Hu R Hui Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysisClin Chem20095511202634

49 

NN Anand V Padma A Prasad KC Alam MS Javid Serum uric acid in new and recent onset primary hypertensionJ Pharm Bioallied Sci20157Suppl 1S48

50 

F Teng R Zhu C Zou Y Xue M Yang H Song Interaction between serum uric acid and triglycerides in relation to blood pressureJ Hum Hypertens2011251168691

51 

JC Nguedia Assob MN Ngowe DS Nsagha AL Njunda Y Waidim DN Lemuh The relationship between uric acid and hypertension in adults in Fako Division, SW region CameroonJ Nutr Food Sci20144110.4172/2155-9600.1000257

52 

P Fagerstrom G Sallsten M Akerstrom B Haraldsson L Barregard Urinary albumin excretion in healthy adults: a cross sectional study of 24-hour versus timed overnight samples and impact of GFR and other personal characteristicsBMC Nephrol201516810.1186/1471-2369-16-8

53 

AH Brantsma SJ Bakker D DeZeeuw PE DeJong RT Gansevoort Urinary albumin excretion as a predictor of the development of hypertension in the general populationJ Am Soc Nephrol20061793315

54 

AH Brantsma SJ Bakker D DeZeeuw PE DeJong RT Gansevoort Extended prognostic value of urinary albumin excretion for cardiovascular eventsJ Am Soc Nephrol2008199178591

55 

TY Wong A Shankar R Klein BE Klein LD Hubbard Prospective cohort study of retinal vessel diameters and risk of hypertensionBMJ2004329745779

56 

WF Keane G Eknoyan Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney FoundationAm J Kidney Dis1999335100410

57 

G Keller G Zimmer G Mall E Ritz K Amann Nephron number in patients with primary hypertensionN Engl J Med200334821018

58 

BM Brenner DL Garcia S Anderson Glomeruli and blood pressure: less of one, more the other?Am J Hypertens198814 Pt 133547

59 

QN Dinh GR Drummond CG Sobey S Chrissobolis Roles of inflammation, oxidative stress, and vascular dysfunction in hypertensionBioMed Res Int20142014406960

60 

VJ Dzau Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesisHypertension2001374104752

61 

GJ Blake N Rifai JE Buring PM Ridker Blood pressure, C-reactive protein, and risk of future cardiovascular eventsCirculation20031082429939

62 

S Chrissobolis FM Faraci Roles of inflammation, oxidative stress, and vascular dysfunction in hypertensionBiomed Res Int2014201440696010.1155/2014/406960



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Review Article


Article page

186-190


Authors Details

Vijatha Thomas*, Arun T Mithrason


Article History

Received : 17-06-2022

Accepted : 07-07-2022


Article Metrics


View Article As

 


Downlaod Files